[Cardiovascular and metabolic toxicity secondary to sorafenib]

Area of Science:

• Oncology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are a key class of chemotherapy agents used for various solid and hematological neoplasms.
• Their mechanism involves inhibiting specific tyrosine kinases essential for neoplastic cell proliferation, offering a targeted approach to cancer treatment.

Observation:

• While generally well-tolerated, TKIs are not entirely selective.
• This lack of selectivity can lead to off-target effects and secondary toxicities in patients.

Findings:

• Sorafenib, a notable TKI, is associated with adverse events including arterial hypertension, thyroid dysfunction, abdominal pain, and hyperamylasemia.
• These side effects highlight the importance of understanding the broader toxicological profile of TKIs.

Implications:

• Regular patient monitoring during TKI therapy is essential for early detection and management of potential side effects.
• Proactive management can improve patient outcomes and adherence to cancer treatment regimens.